spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Bipolar Mania 

 HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 28 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2009
Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2009
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2009
Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2009
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 10 Feb 2009
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2009
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2008
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Biopharmaceuticals
 HSMN NewsFeed - 8 Apr 2008
Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Nov 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2007
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Aug 2007
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 21 Jun 2007
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 20 Dec 2006
INVEGA(TM) Approved By FDA as New Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2006
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2006
U.S. District Court Upholds RISPERDAL(R) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Aug 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY(R) DISCMELT(TM) (aripiprazole)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2006
New Dosages of RISPERDAL(R) (Risperidone) Now Available
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2006
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 mg ABILIFY(R) (aripiprazole) Tablet and Nonrefrigerated Oral Solution
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 33 additional stories matching:
Bipolar Mania
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.